Stock listing
Rallybio Corporation
Selected listing: RLYB · NASDAQ · USD · US
Rallybio Corporation (NASDAQ:RLYB), Health Technology. Latest release Jun 2, 2026: Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger…
- Ticker
- NASDAQ:RLYB
- Asset type
- Stock
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
About Rallybio Corporation
The company focuses on developing innovative therapies to address unmet medical needs. Rallybio is committed to advancing its pipeline of drug candidates aimed at improving patient outcomes.
Latest news from Rallybio Corporation
Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio Corporation - RLYB
June 2, 2026
Rallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Generation Oncology Therapies and $215 Million Concurrent Private Placement
May 31, 2026
Rallybio Corporation and Candid Therapeutics Announce Merger Agreement
March 1, 2026
Rallybio Announces Positive Data for RLYB116 Phase 1 Study Demonstrating Complete and Sustained Inhibition of Terminal Complement
February 17, 2026
Rallybio Announces Reverse Stock Split of Common Stock
February 3, 2026
Research Rallybio Corporation
Rallybio Corporation company profile
View the public company page for Rallybio Corporation on 6ix.
Rallybio Corporation news
Read company news and market updates connected to Rallybio Corporation.
Rallybio Corporation investor events
Find investor webinars, events, and replay context for Rallybio Corporation.